Brief: Valneva Reports Positive Phase 2 Results In Children For Chikungunya Vaccine
10/12/2025 16:49
Dec 10 (Reuters) - Valneva SE VLS.PA: VALNEVA REPORTS POSITIVE FINAL PHASE 2 ANTIBODY PERSISTENCE AND SAFETY RESULTS IN CHILDREN FOR ITS CHIKUNGUNYA VACCINE IXCHIQ® 94.7% SERORESPONSE RATE IN CHIKV-NAÏVE CHILDREN (FULL DOSE) AT DAY 360 Source text: ID:nGNX3n3kBZ Further company coverage: VLS.PA (Gdansk Newsroom) ((gdansk.newsroom@thomsonreuters.com ; +48 58 769 66 00;;))
Recent news on Valneva SE
See all newsBrief: UK MHRA Withdraws Marketing Authorisation for Ixchiq Chikungunya Vaccine After Safety Review
Valneva falls as UK regulator revokes Ixchiq vaccine authorisation
Brief: Valneva Provides Update On Ixchiq® In The United Kingdom
Valneva surges after EU regulator validates Lyme disease vaccine application
Brief: Pfizer And Valneva's Lyme Disease Vaccine Candidate Marketing Authorization Application Validated By European Medicines Agency